SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
AYTU reported Fiscal 2026 (year ended June 30, 2026) results. The price and volatility reaction is pending.
AYTUearnings

Earnings reactions, page 16

Aytu BioPharma, Inc. (AYTU) FY2026 earnings

September 23, 2026 · SharpeIQ Research Desk

Reported results

  • Q4 fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in Q4 fiscal 2025; full year fiscal 2026 net revenue decreased 13.3% to $57.6 million from $66.4 million in fiscal 2025
  • EXXUA net revenue was $6.6 million in full year fiscal 2026 (first full year of commercialization) and $3.9 million in Q4 fiscal 2026
  • Q4 fiscal 2026 EXXUA prescriptions totaled 3,323, up approximately 138% from 1,398 in Q3 fiscal 2026
  • Full year fiscal 2026 GAAP net loss of ($14.3 million), or ($1.16) per share basic and diluted, compared to ($13.6 million), or ($2.16) per share, in fiscal 2025
  • Adjusted EBITDA (non-GAAP) was ($3.7) million for full year fiscal 2026 compared to $9.2 million in fiscal 2025; Q4 fiscal 2026 Adjusted EBITDA (non-GAAP) was $0.5 million compared to $2.0 million in Q4 fiscal 2025
  • Cash and cash equivalents were $26.3 million at June 30, 2026, compared to $31.0 million at June 30, 2025

Notes

On March 31, 2026, the Company amended and restated certain warrants, reducing derivative warrant liabilities by $26.4 million and increasing stockholders’ equity by that same amount. Full year fiscal 2026 results included a $4.7 million derivative warrant liabilities loss, while full year fiscal 2025 included $8.3 million of impairment expense, $2.1 million of restructuring costs and a $1.7 million derivative warrant liabilities loss.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-22 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →